Csr At Novartis
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Csr At Novartis as PDF for free.
More details
- Words: 233
- Pages: 8
CSR at Novartis
Something about Leprosy… • Today only 4 countries face the prevalence of leprosy exceeding one case per 10,000 inhabitants, compared to 122 countries in 1985. • A reduction of almost 98% of leprosy cases reported worldwide in 2007 (compared to 1985) to 225,000. • 2 of the 3 drugs used in MDT were developed by Novartis in their research laboratories.
MDT • Nearly all the global supply of MDT is provided by a collaboration between the WHO and Novartis to cover the period 2000-2005. • Novartis donations helped cure more than 14 million patients since 1985. • Since 2000, Novartis has supplied 41 million blister packs of NDT.
Patients • Patients first • Free product valued at $169 million to 109,000 patients • Free leprosy and tuberculosis treatment and offer the antimalarial drug Coartem without profit through multilateral institutions and public-private partnerships.
Registering the Benchmark • Novartis has registered the East Village buildings and parking garage for LEED (Leadership in Energy and Environmental Design) certification. • LEED is the nationally accepted benchmark for the design, construction and operation of high performance green buildings, developed by the U.S. Green Building Council,
Environmental Care • • • • • •
Energy efficient roof. Recycling waste. Clean renewable sources of energy. CFLs Hybrid Vehicles Solar Array (produces 140,000 KW annually ) • Using Light Sensors
References
• http://www.novartis.com/ • http:// www.who.int/lep/partners/novartis/en/index.htm
Thank You
Something about Leprosy… • Today only 4 countries face the prevalence of leprosy exceeding one case per 10,000 inhabitants, compared to 122 countries in 1985. • A reduction of almost 98% of leprosy cases reported worldwide in 2007 (compared to 1985) to 225,000. • 2 of the 3 drugs used in MDT were developed by Novartis in their research laboratories.
MDT • Nearly all the global supply of MDT is provided by a collaboration between the WHO and Novartis to cover the period 2000-2005. • Novartis donations helped cure more than 14 million patients since 1985. • Since 2000, Novartis has supplied 41 million blister packs of NDT.
Patients • Patients first • Free product valued at $169 million to 109,000 patients • Free leprosy and tuberculosis treatment and offer the antimalarial drug Coartem without profit through multilateral institutions and public-private partnerships.
Registering the Benchmark • Novartis has registered the East Village buildings and parking garage for LEED (Leadership in Energy and Environmental Design) certification. • LEED is the nationally accepted benchmark for the design, construction and operation of high performance green buildings, developed by the U.S. Green Building Council,
Environmental Care • • • • • •
Energy efficient roof. Recycling waste. Clean renewable sources of energy. CFLs Hybrid Vehicles Solar Array (produces 140,000 KW annually ) • Using Light Sensors
References
• http://www.novartis.com/ • http:// www.who.int/lep/partners/novartis/en/index.htm
Thank You
